Autotaxin inhibitors: a perspective on initial medicinal chemistry efforts

Bibliography

• Bollen M, Gijsbers R, Ceulemans H, Nucleotide pyrophosphatases/phosphodiesterases on the move. Crit Rev Biochem Mol Biol 2000;35(6):393-432
   Google Scholar
• Stracke ML, Krutzsch HC, Unsworth EJ, Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein. J Biol Chem 1992;267(4):2524-9
   Google Scholar
• Murata J, Lee HY, Clair T, cDNA cloning of the human tumor motility-stimulating protein, autotaxin, reveals a homology with phosphodiesterases. J Biol Chem 1994;269(48):30479-84
   Google Scholar
• Tokumura A, Majima E, Kariya Y, Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase. J Biol Chem 2002;277(42):39436-42
   Google Scholar
• Umezu-Goto M, Kishi Y, Taira A, Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol 2002;158(2):227-33
   Google Scholar
• Tokumura A, Yamano S, Aono T, Lysophosphatidic acids produced by lysophospholipase D in mammalian serum and body fluid. In: Goetzl EJ, Lynch KR, editors, Lysophospholipids and eicosanoids in biology and pathophysiology. New York Academy of Sciences, New York; 2000. p. 347-50
   Google Scholar
• Tanaka M, Okudaira S, Kishi Y, Autotaxin stabilizes blood vessels and is required for embryonic vasculature by producing lysophosphatidic acid. J Biol Chem 2006;281(35):25822-30
   Google Scholar
• van Meeteren LA, Ruurs P, Stortelers C, Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development. Mol Cell Biol 2006;26(13):5015-22
   Google Scholar
• Koike S, Keino-Masu K, Masu M. Deficiency of autotaxin/lysophospholipase D results in head cavity formation in mouse embryos through the LPA receptor-Rho-ROCK pathway. Biochem Biophys Res Commun 2010;400(1):66-71
   Google Scholar
• Ferry G, Giganti A, Coge F, Functional invalidation of the autotaxin gene by a single amino acid mutation in mouse is lethal. FEBS Lett 2007;581(18):3572-8
   Google Scholar
• Ferry G, Tellier E, Try A, Autotaxin is released from adipocytes, catalyzes lysophosphatidic acid synthesis, and activates preadipocyte proliferation. Up-regulated expression with adipocyte differentiation and obesity. J Biol Chem 2003;278(20):18162-9
   Google Scholar
• Bourgoin SG, Zhao C. Autotaxin and lysophospholipids in rheumatoid arthritis. Curr Opin Investig Drugs 2010;11(5):515-26
   Google Scholar
• Inoue M, Ma L, Aoki J, Autotaxin, a synthetic enzyme of lysophosphatidic acid (LPA), mediates the induction of nerve-injured neuropathic pain. Mol Pain 2008;4:6
   PubMed Web of Science ®Google Scholar
• Inoue M, Xie W, Matsushita Y, Lysophosphatidylcholine induces neuropathic pain through an action of autotaxin to generate lysophosphatidic acid. Neuroscience 2008;152(2):296-8
   Google Scholar
• Okudaira S, Yukiura H, Aoki J. Biological roles of lysophosphatidic acid signaling through its production by autotaxin. Biochimie 2010;92(6):698-706
   Google Scholar
• Samadi N, Bekele R, Capatos D, Regulation of lysophosphatidate signaling by autotaxin and lipid phosphate phosphatases with respect to tumor progression, angiogenesis, metastasis and chemo-resistance. Biochimie. DOI: 10.1016/j.biochi.2010.08.002
   Google Scholar
• Boucher J, Quilliot D, Praderes JP, Potential involvement of adipocyte insulin resistance in obesity-associated up-regulation of adipocyte lysophospholipase D/autotaxin expression. Diabetologia 2005;48(3):569-77
   Google Scholar
• Parrill AL, Baker DL. Autotaxin inhibition: challenges and progress toward novel anti-cancer agents. Anticancer Agents Med Chem 2008;8(8):917-23
   Google Scholar
• Federico L, Pamuklar Z, Smyth SS, Therapeutic potential of autotaxin/lysophospholipase d inhibitors. Curr Drug Targets 2008;9(8):698-708
   Google Scholar
• Harper K, Arsenault D, Boulay-Jean S, Autotaxin promotes cancer invasion via the lysophosphatidic acid receptor 4: participation of the cyclic AMP/EPAC/Rac1 signaling pathway in invadopodia formation. Cancer Res 2010;70(11):4634-43
   Google Scholar
• Vidot S, Witham J, Agarwal R, Autotaxin delays apoptosis induced by carboplatin in ovarian cancer cells. Cell Signal 2010;22(6):926-35
   Google Scholar
• David M, Wannecq E, Descotes F, Cancer cell expression of autotaxin controls bone metastasis formation in mouse through lysophosphatidic acid-dependent activation of osteoclasts. PLoS One 2010;5(3):e9741
   Google Scholar
• Clair T, Koh E, Ptaszynska M, L-histidine inhibits production of lysophosphatidic acid by the tumor-associated cytokine, autotaxin. Lipids Health Dis 2005;4(1):5
   Google Scholar
• Tokumura A, Miyake M, Yoshimoto O, Metal-ion stimulation and inhibition of lysophospholipase D which generates bioactive lysophosphatidic acid in rat plasma. Lipids 1998;33(10):1009-15
   Google Scholar
• Lee HY, Clair T, Mulvaney PT, Stimulation of tumor cell motility linked to phosphodiesterase catalytic site of autotaxin. J Biol Chem 1996;271(40):24408-12
   Google Scholar
• van Meeteren LA, Ruurs P, Christodoulou E, Inhibition of autotaxin by lysophosphatidic acid and sphingosine 1-phosphate. J Biol Chem 2005;280(22):21155-61
   PubMedGoogle Scholar
• Ferry G, Moulharat N, Pradere JP, S32826, a nanomolar inhibitor of autotaxin: discovery, synthesis and applications as a pharmacological tool. J Pharmacol Exp Ther 2008;327(3):809-19
   Google Scholar
• Altman MK, Gopal V, Jia W, Targeting melanoma growth and viability reveals dualistic functionality of the phosphonothionate analogue of carba cyclic phosphatidic acid. Mol Cancer 2010;9:140
   Google Scholar
• Albers HM, van Meeteren LA, Egan DA, Discovery and optimization of boronic acid based inhibitors of autotaxin. J Med Chem 2010;53(13):4958-67
   Google Scholar
• Gierse JK, Thorarensen A, Beltey K, A novel autotaxin inhibitor reduces lysophosphatidic acid levels in plasma and the site of inflammation. J Pharmacol Exp Ther 2010;334(1):310-17
   Google Scholar
• Schiemann K, Schultz M, Staehle W, Preparation of 2,5-diamino-substituted pyrido[4,3-d]pyrimidines as autotaxin inhibitors useful in treating cancer. Merck Patent GmbH, Germany. Application: WO2010063352, 2010. p. 177
   Google Scholar
• Staehle W, Kober I, Schiemann K, Preparation of benzo[b][1,6]naphthyridines as inhibitors of autotaxin for the treatment of tumors. Merck Patent GmbH, Germany. Application: WO, 2010. p. 142
   Google Scholar
• Saunders LP, Ouellette A, Bandle R, Identification of small-molecule inhibitors of autotaxin that inhibit melanoma cell migration and invasion. Mol Cancer Ther 2008;7(10):3352-62
   Google Scholar
• Braddock D. Small molecule inhibitors of autotaxin, and methods of use for the treatment of cancer. Yale University, USA. Application: WO2009151644, 2009. p. 82
   Google Scholar
• Schiemann K, Schultz M, Blaukat A, Preparation of carbamoylthiazoles as anticancer agents. Merck Patent GmbH, Germany. Application: WO2009046842, 2009. p. 102
   Google Scholar
• Hoeglund AB, Bostic HE, Howard AL, Optimization of a pipemidic acid autotaxin inhibitor. J Med Chem 2010;53(3):1056-66
   Google Scholar
• Hoeglund AB, Howard AL, Wanjala IW, Characterization of non-lipid autotaxin inhibitors. Bioorg Med Chem 2010;18(2):769-76
   Google Scholar
• North EJ, Howard AL, Wanjala IW, Pharmacophore development and application toward the identification of novel, small-molecule autotaxin inhibitors. J Med Chem 2010;53(8):3095-105
   Google Scholar
• Jansen S, Stefan C, Creemers JW, Proteolytic maturation and activation of autotaxin (NPP2), a secreted metastasis-enhancing lysophospholipase D. J Cell Sci 2005;118(Pt 14):3081-9
   Google Scholar
• Miller DD, Tigyi GJ, Gududuru V, Acetal phosphate-derived LPA mimics, PPARgamma activators, and autotaxin inhibitors. USA. Application: US2006270634, 2006. p. 21
   Google Scholar
• Prestwich G, Tigyi G, Jiang G, Antitumor alpha -Chloro AND alpha -Bromo phosphonate analogs of lysophosphatidic acid. University of Utah Research Foundation, USA; University of Tennessee Research Foundation. Application: WO2008157361, 2008. p. 65
   Google Scholar
• Parrill-Baker AL, Baker DL, Montedonico LE. Preparation of fluoromethylphenyl phosphodiesters as mechanism-based inactivators of autotaxin. USA. Application: WO2010040080, 2010. p. 38
   Google Scholar
• Takakusa H, Kikuchi K, Urano Y, Design and synthesis of an enzyme-cleavable sensor molecule for phosphodiesterase activity based on fluorescence resonance energy transfer. J Am Chem Soc 2002;124(8):1653-7
   Google Scholar
• Ferguson CG, Bigman CS, Richardson RD, Fluorogenic phospholipid substrate to detect lysophospholipase D/autotaxin activity. Org Lett 2006;8(10):2023-6
   Google Scholar
• Moulharat N, Fould B, Giganti A, Molecular pharmacology of adipocyte-secreted autotaxin. Chem Biol Interact 2008;172(2):115-24
   Google Scholar
• Zhang H, Xu X, Gajewiak J, Dual activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo. Cancer Res 2009;69(13):5441-9
   Google Scholar
• Albers HM, Dong A, van Meeteren LA, Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulation. Proc Natl Acad Sci USA 2010;107(16):7257-62
   Google Scholar
• Jansen S, Andries M, Vekemans K, Rapid clearance of the circulating metastatic factor autotaxin by the scavenger receptors of liver sinusoidal endothelial cells. Cancer Lett 2009;284(2):216-21
   Google Scholar
• Ueda H. Therapeutic or prophylactic agent for generalized pain syndrome. Nagasaki University, Japan; Argenes, Inc. Application: WO2010016590, 2010. p. 48
   Google Scholar